Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Esco2 restrains pathological endothelial-mesenchymal transition through hidden isoform regulation in a Roberts syndrome model
Roy Jung, Sherin Saheera, Chinmay M. Trivedi
Roy Jung, Sherin Saheera, Chinmay M. Trivedi
View: Text | PDF
Research Article Cell biology Development Vascular biology

Esco2 restrains pathological endothelial-mesenchymal transition through hidden isoform regulation in a Roberts syndrome model

  • Text
  • PDF
Abstract

Roberts syndrome is caused by biallelic ESCO2 pathogenic variants, but the mechanisms linking ESCO2 loss to embryonic endothelial failure remain poorly defined. Endothelial cells must maintain identity and resist endothelial-mesenchymal transition (EndMT), yet conventional transcriptomics measures gene abundance rather than isoform composition. Here, using endothelial-specific Esco2 deletion in a mouse model relevant to Roberts syndrome, we show that Esco2 loss causes yolk sac vascular remodeling failure, pathological EndMT, diversion from hemogenic endothelial fate, hemogenic endothelial depletion, impaired hematopoietic output, and embryonic lethality. Short-read single-cell RNA-seq revealed broad endothelial reprogramming, whereas single-cell long-read isoform sequencing uncovered a hidden layer of isoform dysregulation that conventional gene-level analysis failed to resolve. Esco2-deficient endothelium exhibited transcriptome-wide isoform switching, disruption of a multi-tier splicing-factor network, and predicted broad loss or rewiring of protein-coding output. Chromatin occupancy profiling localized Esco2 to exonic regions near alternatively spliced loci, supporting a cotranscriptional route to spliceopathy. Whole-genome sequencing showed that local DNA variation was insufficient to explain these changes, supporting a predominantly posttranscriptional mechanism. These findings identify isoform control as a disease-relevant layer of endothelial identity maintenance in Roberts syndrome.

Authors

Roy Jung, Sherin Saheera, Chinmay M. Trivedi

×

Figure 2

Esco2 loss remodels the yolk sac vascular compartment and promotes pathological EndMT.

Options: View larger image (or click on image) Download as PowerPoint
Esco2 loss remodels the yolk sac vascular compartment and promotes patho...
(A) UMAP of 8,959 E9.5 yolk sac cells from control and Esco2F/F;Lyve1-Cre samples annotated into 26 clusters using established markers. (B) Cluster-abundance log2 fold changes. EndMT_late_1 expanded 41.5-fold, whereas Hemogenic EC decreased to 0.50-fold. EndMT_late_1 expressed Fbn1, Col3a1, and Mecom with weak residual Efnb2 and Vwf; EndMT_late_2 expressed Col3a1 with minimal other lineage markers. (C) Vascular compartment composition by genotype (χ² = 527.7, P = 9.2 × 10–¹¹¹; χ2 test of homogeneity). (D) Endothelial gene expression in YS Plexus EC and Hemogenic EC. In Hemogenic EC, Ramp2, Id3, Lyve1, and Gng11 were significantly reduced; in YS Plexus EC, only Id3 reached transcriptome-wide adjusted significance. Cdh5, Emcn, and Klf2 were unchanged. Endothelial identity module scores did not differ significantly between genotypes (2-sided Wilcoxon rank-sum test with Bonferroni correction). (E) Mesenchymal gene expression across YS Plexus EC, Hemogenic EC, EndMT_early, EndMT_mid, EndMT_late_1, and EndMT_late_2. Acta2, Tagln, Col1a1, Col3a1, Fbn1, Lum, and Twist2 showed progressively increased expression across the EndMT-associated continuum. (F) Immunofluorescence of E9.5 yolk sacs for Lyve1 (green), SMA (red), GFP (gray), and Hoechst (blue). Mutants showed increased SMA staining (red arrows). GFP marks Lyve1-Cre–recombined cells and descendants. Images are representative of 3 independent yolk sacs per genotype. Scale bar: 10 μm. (G) Endothelial identity versus EndMT module scores in individual YS Plexus EC and Hemogenic EC cells. Control cells showed a weak positive correlation (ρ = 0.124, P = 0.019), whereas Esco2F/F;Lyve1-Cre cells showed a negative correlation (ρ = −0.273, P = 5.1 × 10–6; 2-sided Spearman correlation).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts